• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

爱尔兰慢性疾病管理:大型溃疡性结肠炎人群的住院率和临床结局。

Managing chronic disease in Ireland: hospital admission rates and clinical outcomes in a large ulcerative colitis population.

机构信息

Department of Medicine, Alimentary Pharmabiotic Centre, Cork University Hospital, University College Cork, National University of Ireland, Wilton, Cork, Ireland.

出版信息

Ir J Med Sci. 2012 Mar;181(1):65-71. doi: 10.1007/s11845-011-0760-y. Epub 2011 Sep 24.

DOI:10.1007/s11845-011-0760-y
PMID:21947686
Abstract

BACKGROUND

Health care planning demands a detailed knowledge of the course of chronic diseases in the Irish population. This study describes hospital admission rates, medication use and outcomes in a large cohort of patients with ulcerative colitis attending a tertiary referral centre in Ireland.

METHOD

Four hundred and twenty-four patients who attended during the 18-year period from January 1991 to January 2009 were identified. Baseline demographics, hospital admission, medications required, extent of colitis and date of colectomy were recorded.

RESULTS

More than half (55.4%) of the patients were managed exclusively in an outpatient setting throughout diagnosis and follow-up. Systemic corticosteroids, thiopurines and infliximab were required by 70, 29.5 and 5% of the patients, respectively. Overall 5-year colectomy rate due to failure of medical therapy was 15.8%. Independent predictors of colectomy were hospital admission at first presentation (odds ratio 3.6, p < 0.0001) and pancolitis at diagnosis (odds ratio 2.3, p < 0.01).

CONCLUSIONS

The majority of patients with colitis have an uncomplicated disease course and do not require thiopurines, biologic agents or hospital admission. Principal management at a primary care level may be appropriate in many cases. Colectomy rates at a specialist centre in Ireland compare favourably with international figures.

摘要

背景

医疗保健规划需要详细了解爱尔兰人群中慢性病的病程。本研究描述了在爱尔兰一家三级转诊中心就诊的大量溃疡性结肠炎患者的住院率、药物使用和结局。

方法

从 1991 年 1 月至 2009 年 1 月的 18 年期间,确定了 424 名就诊患者。记录了基线人口统计学、住院、所需药物、结肠炎程度和结肠切除术日期。

结果

超过一半(55.4%)的患者在整个诊断和随访期间仅在门诊接受治疗。分别有 70%、29.5%和 5%的患者需要全身皮质类固醇、硫嘌呤和英夫利昔单抗。由于药物治疗失败,总体 5 年结肠切除术率为 15.8%。结肠切除术的独立预测因素为首次就诊时住院(优势比 3.6,p<0.0001)和诊断时全结肠炎(优势比 2.3,p<0.01)。

结论

大多数结肠炎患者的疾病过程较为简单,不需要硫嘌呤、生物制剂或住院治疗。在许多情况下,初级保健一级的主要管理可能是合适的。爱尔兰一家专科中心的结肠切除术率与国际数据相比情况较好。

相似文献

1
Managing chronic disease in Ireland: hospital admission rates and clinical outcomes in a large ulcerative colitis population.爱尔兰慢性疾病管理:大型溃疡性结肠炎人群的住院率和临床结局。
Ir J Med Sci. 2012 Mar;181(1):65-71. doi: 10.1007/s11845-011-0760-y. Epub 2011 Sep 24.
2
Infliximab in ulcerative colitis: the impact of preoperative treatment on rates of colectomy and prescribing practices in the province of British Columbia, Canada.英夫利昔单抗治疗溃疡性结肠炎:术前治疗对不列颠哥伦比亚省结肠切除术率和处方实践的影响,加拿大。
Dis Colon Rectum. 2014 Jan;57(1):83-90. doi: 10.1097/DCR.0000000000000003.
3
Efficacy of infliximab in acute severe ulcerative colitis: a single-centre experience.英夫利昔单抗治疗急性重度溃疡性结肠炎的疗效:单中心经验。
World J Gastroenterol. 2013 Feb 21;19(7):1091-7. doi: 10.3748/wjg.v19.i7.1091.
4
Long-term prognosis of ulcerative colitis and its temporal changes between 1986 and 2015 in a population-based cohort in the Songpa-Kangdong district of Seoul, Korea.韩国首尔松坡-江东地区基于人群队列的溃疡性结肠炎长期预后及其在1986年至2015年间的时间变化
Gut. 2020 Aug;69(8):1432-1440. doi: 10.1136/gutjnl-2019-319699. Epub 2019 Dec 10.
5
Impact of thiopurines on the natural history and surgical outcome of ulcerative colitis: a cohort study.硫嘌呤类药物对溃疡性结肠炎自然病程和手术结局的影响:一项队列研究。
Gut. 2019 Apr;68(4):623-632. doi: 10.1136/gutjnl-2017-315521. Epub 2018 Apr 4.
6
Colectomy rate in acute severe ulcerative colitis in the infliximab era.英夫利昔单抗时代急性重症溃疡性结肠炎的结肠切除术发生率。
Dig Liver Dis. 2008 Oct;40(10):821-6. doi: 10.1016/j.dld.2008.03.014. Epub 2008 May 9.
7
Inpatient infliximab is ineffective at preventing colectomy for steroid refractory extensive colitis.住院患者使用英夫利昔单抗预防激素难治性广泛性结肠炎行结肠切除术无效。
J Surg Res. 2017 Nov;219:18-24. doi: 10.1016/j.jss.2017.05.077. Epub 2017 Jun 21.
8
Use of infliximab in the prevention and delay of colectomy in severe steroid dependant and refractory ulcerative colitis.英夫利昔单抗在预防和延缓重度激素依赖型及难治性溃疡性结肠炎患者结肠切除术方面的应用
World J Gastroenterol. 2008 Apr 28;14(16):2544-9. doi: 10.3748/wjg.14.2544.
9
Managing paediatric acute severe ulcerative colitis according to the 2011 ECCO-ESPGHAN guidelines: Efficacy of infliximab as a rescue therapy.根据2011年欧洲克罗恩病和结肠炎组织(ECCO)-欧洲儿科胃肠病、肝病和营养学会(ESPGHAN)指南管理儿童急性重症溃疡性结肠炎:英夫利昔单抗作为挽救治疗的疗效
Dig Liver Dis. 2015 Jun;47(6):455-9. doi: 10.1016/j.dld.2015.01.156. Epub 2015 Feb 4.
10
Cyclosporine or infliximab as rescue therapy in severe refractory ulcerative colitis: early and long-term data from a retrospective observational study.环孢素或英夫利昔单抗作为重度难治性溃疡性结肠炎的挽救治疗:来自回顾性观察研究的早期和长期数据。
J Crohns Colitis. 2012 Jul;6(6):681-6. doi: 10.1016/j.crohns.2011.11.021. Epub 2012 Jan 13.

引用本文的文献

1
A Systematic Review of the Economic and Health-Related Quality of Life Impact of Advanced Therapies Used to Treat Moderate-to-Severe Ulcerative Colitis.用于治疗中重度溃疡性结肠炎的先进疗法的经济学和健康相关生活质量影响的系统评价。
Adv Ther. 2023 May;40(5):2116-2146. doi: 10.1007/s12325-023-02488-z. Epub 2023 Mar 31.
2
Anti-TNF alpha in the treatment of ulcerative colitis: a valid approach for organ-sparing or an expensive option to delay surgery?抗肿瘤坏死因子α治疗溃疡性结肠炎:保留器官的有效方法还是延迟手术的昂贵选择?
World J Gastroenterol. 2014 May 7;20(17):4839-45. doi: 10.3748/wjg.v20.i17.4839.

本文引用的文献

1
Steroid dependency and pediatric inflammatory bowel disease in the era of immunomodulators--a population-based study.免疫调节剂时代的类固醇依赖和儿童炎症性肠病——一项基于人群的研究。
Inflamm Bowel Dis. 2011 Aug;17(8):1731-40. doi: 10.1002/ibd.21559. Epub 2010 Dec 3.
2
European evidence-based Consensus on the management of ulcerative colitis: Current management.欧洲溃疡性结肠炎管理循证共识:当前管理措施
J Crohns Colitis. 2008 Mar;2(1):24-62. doi: 10.1016/j.crohns.2007.11.002. Epub 2008 Jan 18.
3
European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis.
欧洲溃疡性结肠炎诊断与管理循证共识:定义与诊断
J Crohns Colitis. 2008 Mar;2(1):1-23. doi: 10.1016/j.crohns.2007.11.001. Epub 2008 Jan 18.
4
The pattern and outcome of acute severe colitis.急性重症结肠炎的模式和结果。
J Crohns Colitis. 2010 Oct;4(4):431-7. doi: 10.1016/j.crohns.2010.02.001. Epub 2010 Feb 19.
5
The efficacy of low dose azathioprine/6-mercaptopurine in patients with inflammatory bowel disease.低剂量硫唑嘌呤/6-巯基嘌呤对炎症性肠病患者的疗效。
Hepatogastroenterology. 2009 Sep-Oct;56(94-95):1395-402.
6
Adverse events of IBD therapies.炎症性肠病治疗的不良事件。
Inflamm Bowel Dis. 2008 Oct;14 Suppl 2:S210-1. doi: 10.1002/ibd.20702.
7
Disorders of a modern lifestyle: reconciling the epidemiology of inflammatory bowel diseases.现代生活方式紊乱:调和炎症性肠病的流行病学
Gut. 2008 Sep;57(9):1185-91. doi: 10.1136/gut.2007.122143. Epub 2008 May 30.
8
Colectomy rate in acute severe ulcerative colitis in the infliximab era.英夫利昔单抗时代急性重症溃疡性结肠炎的结肠切除术发生率。
Dig Liver Dis. 2008 Oct;40(10):821-6. doi: 10.1016/j.dld.2008.03.014. Epub 2008 May 9.
9
Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing.硫唑嘌呤在炎症性肠病中的治疗:临床药理学及药物基因组学指导给药的意义
Clin Pharmacokinet. 2007;46(3):187-208. doi: 10.2165/00003088-200746030-00001.
10
Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years.在一个未经挑选的欧洲队列中,溃疡性结肠炎患者接受低位结肠切除术的比例随访了10年。
Gastroenterology. 2007 Feb;132(2):507-15. doi: 10.1053/j.gastro.2006.11.015. Epub 2006 Nov 15.